N/A N=22 Diagnosing Intensive Care Unit (ICU) Acquired Weakness
ICU Acquired Weakness
Primary: Peak Acceleration Measured in Extensor Carpi Radialis Longus — 0.476; 1.639; 0.541; 1.608 units of Gravity
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=96 Evaluation of Anterior Quadratus Lumborum Block for Postoperative Analgesia in Hip Arthroscopy
Hip Disease
Primary: Numerical Pain Rating System (NRS) Pain Scores — 3.3; 4.4; 4.5; 4.7 score on a scale
N/A N=60 Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound
Peripheral Artery Disease
Primary: Change in Minimal Luminal Area — 5.8; 4 mm^2
N/A N=10 The Care After Life-threatening Medical Events Study
Cardiac Arrest · Fear
Primary: Percentage of Eligible Cardiac Arrest (CA) Survivors Whom we Approach Who Ultimately Agree to Participate in the Pilot Study — 83.33 percentage of participants who…
Phase 3 N=800 Hydrocortisone for BPD
Infant, Newborn · Infant, Small for Gestational Age · Infant, Very Low Birth Weight
Primary: Survival Without Moderate/Severe Physiologic Bronchopulmonary Dysplasia (BPD) — 332; 349; 66; 53 Participants
Phase 2 N=29 Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: PFS Rate — 54.6 percentage of patients
Phase 2 N=332 Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants Experiencing ≥1 Treatment-emergent Adverse Event (TEAE) — 104; 60 Participants
Phase 3 N=300 Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1
Hepatorenal Syndrome
Primary: Percentage of Participants With Verified HRS Reversal — 29.1; 15.8 percentage of participants
N/A N=99 LIBERATE International
Stress Urinary Incontinence
Primary: CFB in 1-hour Pad Weight Test — -8.1; -8.1 grams
Phase 4 N=81 Vorapaxar on Thrombin Generation and Coagulability
Coronary Artery Disease · Peripheral Vascular Disease · Myocardial Infarction
Primary: Effects of Vorapaxar on 15 μmol/L SFLLRN (PAR-1 Activating Peptide) Induced Platelet Aggregation — 8; 5; 5; 4 Maximum aggregation (%)
N/A N=28 Patient-caregiver Communication Intervention for Prognostic Understanding
Advanced Cancer
Primary: Change in Prognostic Understanding — 0.00; 0.25 Change in scores on a scale
Phase 3 N=148 Increased Ketorolac Administration After Cesarean Section and Its Effect on Opioid Use: a Randomized Control Trial
Post-operative Pain · Post-partum Pain · Cesarean Section Complications
Primary: The Total Morphine Milligram Equivalents (MME) Used in the First 72 Postoperative Hours — 60.0; 30 MME
Phase 2 N=310 Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
Refractory and/or Unexplained Chronic Cough
Primary: Change From Baseline in 24-hour Cough Count After 12 Weeks of Intervention — 0.56; 0.47; 0.52; 0.64 Ratio btw geoMeans of 24h cough count — p== 0.0345
Phase 2 N=67 Translational Neuropsychopharmacology Research of Nicotine Addiction
Nicotine Dependence, Cigarettes
Primary: Percent Change in Blood Oxygen Level Dependent (BOLD) Signal Response — -0.09; 1.07; 0.08; 1.19 Percentage change
N/A N=101 Gender Difference in Response to Caffeine in Children and Adolescents
Healthy
Primary: Peak Heart Rate After 2 mg/kg of Caffeine — 73.6; 73.2; 79.6 beats per minute — p=<0.05